Purpose We conducted a systematic review of the literature in order to take stock of hip resurfacing according to the principle of "evidence based medicine". Our main objective was to compare the rate of revision of resurfacing implants with survival limits set by the National Institute of Clinical Excellence (NICE). Methods A systematic review was undertaken of all published (Medline, Cochrane, EMBASE) literature research databases up to July 2012 as recommended by the PRISMA statement. Data extraction focused on functional outcomes, complications and survival rates. The survival rates of implants were analysed according to the mean of the series in comparison to the NICE criteria. Results Fifty-three studies were identified and included 26,456 cases with an average of 499.17 ± 856.7 (range, 38-5000) cases per study. The median survival was 95.57 % ± 3.7 % (range, 84-100). The percentage of studies which satisfied the criteria set by NICE was 69.8 %. In terms of cumulative revision rates pondered by the number of implants, BHR®, Conserve Plus® and Cormet® showed the best results. The mean postoperative score was 91. 2 ± 7.72 (range, 68.3-98.6). There was no statistically significant difference between implants in terms of functional outcomes. Conclusion On the basis of the current evidence base, this review of the literature emphasises the importance of certain parameters that can improve the results of resurfacing. The type of implant seems to play an important role as does patient selection.
Introduction
After a period of popularity, hip resurfacing has seen a number of indications to be decreasing [1] . It is currently the subject of numerous concerns with regards to the presence of metal ions in the blood, even if there is no conclusive evidence of a carcinogenic effect [2] . Furthermore, many publications seem to show excellent results. We conducted a systematic review of the literature in order to take stock of this surgical technique according to the principle of "evidence based medicine."
Our main objective was to compare the rate of revision of resurfacing implants with survival limits set by the National Institute of Clinical Excellence (NICE) (maximum of 10 % at ten years), being part of the National Health System (NHS) in England and Wales [3] [4] [5] . The secondary objectives were to evaluate the functional outcome and complications associated with hip resurfacing as well as differences between these implants.
Materials and methods
The research was conducted on July 14, 2012 using the Cochrane databases, EMBASE and MEDLINE as recommended by The PRISMA statement [6] . The electronic search included articles published until 25 July 2012. The following terms used the joints "AND", "NOT" and "OR": hips, femur head, femoral head, femur neck, femoral neck, resurfac* outcome, follow-up, FU, prosthesis failure, pseudotumor, pseudotumour, mechanical stress, gait, patient satisfaction, activity, activities, surviv* and risk factors. All titles and abstracts were reviewed by a single observer, and for studies meeting eligibility criteria the full article was obtained. The reference lists of meta-analysis and systematic reviews of the literature were examined to avoid missing studies not identified by the search. The inclusion criteria were: publication in English and studies reporting survival or revision of the implant with a minimum of at least six-months follow up. Exclusion criteria were: studies on hemi-arthroplasty, studies reporting results after revision of a resurfacing, retrospective studies on implant failures, technical note type studies, studies reporting only laboratory results, histological studies, in-vitro simulation study, bioengineering studies, radiological studies, studies of national registries, and clinical case studies of peri-prosthetic bone density. If articles described the same series of patients, we included the most recently published series with the largest number of patient population. The criteria for inclusion/ exclusion was controlled by two different observers with the inclusion of a third in case of disagreement. Data extraction focused on the type of prosthesis, the design of the study, the baseline characteristics of patients, the mean follow-up, functional scores, survival rates, and the type and number of complications. Functional scores were standardised as far as possible on a scale of 0 to 100, with 100 representing the best possible functional outcome. The survival rate of implants was analysed according with respect to the mean of the series and compared with the NICE criteria. Quality of studies, in terms of level of evidence, was judged using the GRADE evaluation system (Grading of Recommendations Assessment, Development and Evaluations) classifying the quality of education in high, moderate, low and very low [7] . Mackenzie et al. [37] Comparative study which was only in use around 1996. One study compared the BHR® implant to the Recap® implant (Biomet Inc., Warsaw, Indiana). The data presented only six of the 11 resurfacing devices currently on the market. We were not able to identify studies that met our inclusion/exclusion for ACCIS® implants (Implantcast GmbH, Buxtehude, Germany), Adept® (Finsbury Orthopaedics), EskaBionik® (Eska Implants, Lübeck, Germany), Icon® (International Orthopaedics, Geisingen, Germany), and Mitch® (Stryker, Kalamazoo, Michigan).
Three randomised clinical trials and eight comparative studies compared the results of resurfacing implants to conventional total hip arthroplasty. The average survival rate for resurfacing implants was 94.84 % ± 4.7 (range, 89.1-100) Another study analysed a prospective series of 660 procedures with BHR® implants, ASR® and ASR® THA implants. This study found that 17 patients needed a revision (ASR® implant in all cases). The revision rate was 0 % for the BHR® implant, 3.2 % for ASR® and 6 % for THA® ASR. Steiger et al. [9] found similar results. The cumulative revision rate at five years was 10.9 % (95 % CI, 8.7-13.6) with the ASR implant and 4 % (95 % CI, 3.7-4.5) for other resurfacing implants. The cumulative revision rate due to metallosis was 1.7 % (95 % CI, 0.9-3.1) with the ASR® implant against 0.3 % (95 % CI, 0.2-0.5) for other implants.
Thirty-seven studies reported single arm results in terms of survival/revision for the different resurfacing implants (Table 1) .
Of all the studies, the total number of resurfacing performed was 26,456 and the average number of cases per study was 499.17 ± 856.7 (range, 38-5000). The mean follow up was 4.3±2.54 (range, 0.6-10.5) years. The average age of patients was 50.75 years ±5.19 (range, . The percentage of males per study was 64.73 % ± 13.55 (range, 28-95). The median survival was 95.57 % ±3.7 (range, 84-100). The percentage of studies which satisfied the criteria set by NICE was 69.8 %. In terms of cumulative revision rates pondered by the number of implants BHR®, Conserve Plus®, Cormet® showed the best results (Figs. 2, 3, 4, and 5) .
The details of the functional results for each study are reported in Table 2 . The mean postoperative score was 91.2 ± 7.72 (range, 68.3-98.6). There was no statistically significant difference between implants in terms of functional outcomes.
The revision rate was 4.4 % if we considered all cases in these published series. The most frequent complications (Table 3 ; Fig. 6 ) were aseptic loosening 33.5 %, followed by femoral fractures.
According to the GRADE recommendation system, the quality of these studies in terms of level of evidence was very low except for a randomised clinical trial where the quality of results reported was low [7] . We could only find long-term studies for three types of implants: BHR, Conserve Plus, and Cormet. For these implants revision rates seemed to fit the criteria for NICE benchmarks. The implant ReCap had excellent results at 2.9 years of mean follow-up. The randomised clinical trial comparing the results of the Durom implant with those of a THA reported a higher rate of revision for the resurfacing implant. However, the difference was not statistically significant. The ASR implant did not fulfill the NICE criteria in any study.
Discussion
It is interesting to compare the results from the different national registries.
The Nordic Arthroplasty Register Association [10] has three national registries: Danish, Swedish and Norwegian. The total number of total hip replacements performed between 1995 and 2007 has reached a figure of 280,201, of which only 0.5 % represented resurfacing [61] . The revision rate at two years was reported as 2.4 % for all resurfacing vs 1.1 % for conventional THA. The main complications for resurfacings outlined were fractures and aseptic loosening. The Nordic register also highlighted a survival rate significantly higher in those centres performing greater than 70 cases per annum (98.8 %) than those performing fewer (95.5 %).
Analysis of the Australian register by Prosser et al. [1] succeeded the one of Buergi et al. [62] and examined 12,093 hip resurfacings performed between 1999 and 2008. The results were compared with those of conventional THA performed during the same period. Analysis of the registry showed that women had a higher revision rate than men. However, after adjusting the size of the femoral component [44] found themselves documenting similar results for implants of smaller head sizes of less than 50 mm. The type of implant seemed to have an influence on the results. Durom implants, ASR, Cormet 2000 HAP and Recap had a higher revision rate and higher risk of fractures; this was statistically significant in comparison to other implants. The implant with the lowest fracture rate was the BHR implant with a five-year rate of 1.2 % (range, 1.0-1.5) against 3 % for ASR (range, 2-5), 2 % for Durom (range, 1-4 ) and 3 % (range, 1-9) for Recap. After adjusting for possible confounding factors, it appeared that the differences were only related to the designs of implants and surgical technique when preparing the femoral head. Finally, the registry highlighted that dysplastic hips were at a higher risk of revision. Analysis of the English register was made by McMinn et al. [63] and included 283,365 procedures with a mean follow up of 3.6 years (range, 0.01-9.7). The objective of this analysis was unlike other registries, not only to study the revision rates after adjustment (with sex, age, size of implants, ASA / American Society of Anesthesiologists grade) but also to study the mortality rate. After adjusting for all known risk factors for revision surgery, mortality in men was statistically lower for the BHR implant in comparison to the uncemented THA group. The authors concluded for every 23 cases (males), there will be one less death in the BHR group in comparison to the cemented THA group at six years follow up.
In our review the percentage of studies that met the NICE criteria was 69.8 %. The average survival rate in these studies was significantly higher than the national registries. One explanation for this difference is that these studies are often single-operator led being experienced surgeons themselves. The most important series highlighted are those from design centres, which probably introduces a confounding factor.
However, analysis of records despite the large number of prosthesis is not provided to overestimate the information they provide. Indeed there are many confounding factors and bias that can lead to misinterpretation of the results.
First, record completeness is not guaranteed. So if the data collection seems close to 95 % for northern registers, it would be only 30 % for British records [64] .
Second, the failure criteria is often the revision of the implant for whatever reason. This criteria is not necessarily impartial. This is because the sensitivity of the revision rate for clinical failure (insufficient functional score) is not identical between a resurfacing implant and a conventional total hip replacement. For example, as for knee arthroplasties, for hips with a poor functional outcome (HHS <30), only 12 % of THA may have been revised, as compared to 63 % of resurfacing with a similar score [63] [64] [65] . This calls into question the use of the revision rate for objectively comparing these two types of implants.
Third, the records do not account for the learning curve associated with the use of new implants [41, 66, 67] . Indeed for the implants on the market for over ten years there is no implication of a learning curve within the data held in the registries.
Finally, essential information is often missing: history of the patients, the ASA score, radiographic positioning of the implants, the presence of osteolysis, etc. This information is vital to determine the cause of failure, groups at risk and to compare similar groups of patients after adjustment for these criteria. In conclusion, this review of the literature emphasises the importance of certain parameters that can improve the results of resurfacing. The type of implant seems to play an important role as does patient selection. This should be based more on the expected size of the implant rather than the gender. Finally, it is clear that the resurfacing implants require a significant learning curve and implants are less "tolerant" than conventional THA, particularly for the orientation of the acetabular component [44, 61, 68] .
